FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093682459> ?p ?o ?g. }

• W2093682459 endingPage "12" @default.
• W2093682459 startingPage "12" @default.
• W2093682459 abstract "In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis.Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points.A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March 2019), 188 patients (67%) receiving osimertinib versus 93 (66%) receiving platinum–pemetrexed had died. The hazard ratio (HR) for OS was 0.87 [95% confidence interval (CI) 0.67–1.12; P = 0.277]; the median OS was 26.8 months (95% CI 23.5–31.5) versus 22.5 months (95% CI 20.2–28.8) for osimertinib and platinum–pemetrexed, respectively. The estimated 24- and 36-month survival was 55% versus 43% and 37% versus 30%, respectively. After crossover adjustment, there was an HR of 0.54 (95% CI 0.18–1.6). Time to first subsequent therapy or death showed a clinically meaningful advantage toward osimertinib (HR 0.21, 95% CI 0.16–0.28; P < 0.001). At DCO, 99/136 (73%) patients in the platinum–pemetrexed arm had crossed over to osimertinib, 66/99 (67%) of whom had died. The most common adverse events possibly related to study treatment were diarrhea (32%; grade ≥3, 1%) and rash (grouped term; 32%; grade ≥3, <1%) in the osimertinib arm, versus nausea (47%; grade ≥3, 3%) in the platinum–pemetrexed arm.In patients with T790M advanced NSCLC, no statistically significant benefit in OS was observed for osimertinib versus platinum–pemetrexed, which possibly reflects the high crossover rate of patients from platinum–pemetrexed to osimertinib.ClinicalTrials.gov NCT02151981; https://clinicaltrials.gov/ct2/show/NCT02151981." @default.
• W2093682459 created "2016-06-24" @default.
• W2093682459 creator A5002750249 @default.
• W2093682459 creator A5005936736 @default.
• W2093682459 creator A5011136538 @default.
• W2093682459 creator A5070980712 @default.
• W2093682459 creator A5077706003 @default.
• W2093682459 date "2006-05-01" @default.
• W2093682459 modified "2023-09-25" @default.
• W2093682459 title "Inflammatory biomarkers for persistent fatigue in breast cancer survivors" @default.
• W2093682459 cites W118686632 @default.
• W2093682459 cites W1494692328 @default.
• W2093682459 cites W1554944419 @default.
• W2093682459 cites W1566293442 @default.
• W2093682459 cites W1948268265 @default.
• W2093682459 cites W1963720781 @default.
• W2093682459 cites W1973130052 @default.
• W2093682459 cites W1978345359 @default.
• W2093682459 cites W1982657650 @default.
• W2093682459 cites W1986632581 @default.
• W2093682459 cites W1992350503 @default.
• W2093682459 cites W1994025593 @default.
• W2093682459 cites W1995582130 @default.
• W2093682459 cites W2008489516 @default.
• W2093682459 cites W2009819148 @default.
• W2093682459 cites W2014593621 @default.
• W2093682459 cites W2016699711 @default.
• W2093682459 cites W2017352677 @default.
• W2093682459 cites W2018374163 @default.
• W2093682459 cites W2023505415 @default.
• W2093682459 cites W2026889886 @default.
• W2093682459 cites W2029520384 @default.
• W2093682459 cites W2034137314 @default.
• W2093682459 cites W2035121795 @default.
• W2093682459 cites W2062539824 @default.
• W2093682459 cites W2066823109 @default.
• W2093682459 cites W2081282655 @default.
• W2093682459 cites W2090363571 @default.
• W2093682459 cites W2106787323 @default.
• W2093682459 cites W2119968490 @default.
• W2093682459 cites W2128416931 @default.
• W2093682459 cites W2130559643 @default.
• W2093682459 cites W2130838084 @default.
• W2093682459 cites W2133957868 @default.
• W2093682459 cites W2137729498 @default.
• W2093682459 cites W2142449120 @default.
• W2093682459 cites W2158838767 @default.
• W2093682459 cites W2158860532 @default.
• W2093682459 cites W2171467964 @default.
• W2093682459 cites W2408880198 @default.
• W2093682459 cites W48451113 @default.
• W2093682459 cites W2056930167 @default.
• W2093682459 doi "https://doi.org/10.1016/j.bbi.2006.04.023" @default.
• W2093682459 hasPublicationYear "2006" @default.
• W2093682459 type Work @default.
• W2093682459 sameAs 2093682459 @default.
• W2093682459 citedByCount "0" @default.
• W2093682459 crossrefType "journal-article" @default.
• W2093682459 hasAuthorship W2093682459A5002750249 @default.
• W2093682459 hasAuthorship W2093682459A5005936736 @default.
• W2093682459 hasAuthorship W2093682459A5011136538 @default.
• W2093682459 hasAuthorship W2093682459A5070980712 @default.
• W2093682459 hasAuthorship W2093682459A5077706003 @default.
• W2093682459 hasConcept C121608353 @default.
• W2093682459 hasConcept C126322002 @default.
• W2093682459 hasConcept C143998085 @default.
• W2093682459 hasConcept C207103383 @default.
• W2093682459 hasConcept C2776256026 @default.
• W2093682459 hasConcept C2776694085 @default.
• W2093682459 hasConcept C2777240266 @default.
• W2093682459 hasConcept C2777626846 @default.
• W2093682459 hasConcept C2778087573 @default.
• W2093682459 hasConcept C2778239845 @default.
• W2093682459 hasConcept C2779438470 @default.
• W2093682459 hasConcept C2780739268 @default.
• W2093682459 hasConcept C2781451048 @default.
• W2093682459 hasConcept C44249647 @default.
• W2093682459 hasConcept C71924100 @default.
• W2093682459 hasConcept C90924648 @default.
• W2093682459 hasConceptScore W2093682459C121608353 @default.
• W2093682459 hasConceptScore W2093682459C126322002 @default.
• W2093682459 hasConceptScore W2093682459C143998085 @default.
• W2093682459 hasConceptScore W2093682459C207103383 @default.
• W2093682459 hasConceptScore W2093682459C2776256026 @default.
• W2093682459 hasConceptScore W2093682459C2776694085 @default.
• W2093682459 hasConceptScore W2093682459C2777240266 @default.
• W2093682459 hasConceptScore W2093682459C2777626846 @default.
• W2093682459 hasConceptScore W2093682459C2778087573 @default.
• W2093682459 hasConceptScore W2093682459C2778239845 @default.
• W2093682459 hasConceptScore W2093682459C2779438470 @default.
• W2093682459 hasConceptScore W2093682459C2780739268 @default.
• W2093682459 hasConceptScore W2093682459C2781451048 @default.
• W2093682459 hasConceptScore W2093682459C44249647 @default.
• W2093682459 hasConceptScore W2093682459C71924100 @default.
• W2093682459 hasConceptScore W2093682459C90924648 @default.
• W2093682459 hasIssue "3" @default.
• W2093682459 hasLocation W20936824591 @default.
• W2093682459 hasOpenAccess W2093682459 @default.

• next